Month: July 2025

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk’s executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk’s International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk’s affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: “Mike is...

ZOOZ to become the first Nasdaq and TASE dual-listed company to hold Bitcoin in its treasury The Board of Directors of the Company has approved the new strategy, which provides investors with exposure to Bitcoin Jordan Fried to become CEO to lead the first Israeli digital asset treasury strategy Largest offering by a Non-US Listed Company to launch a digital asset treasury strategy TEL AVIV, Israel, July 29, 2025 (GLOBE NEWSWIRE) — ZOOZ Power Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced a $180 million private placement, or PIPE, with accredited institutional investors in connection with its plans to launch a Bitcoin Reserve Strategy. The PIPE, which is subject to shareholders’ approval, is expected to involve the sale of 180 million of the Company’s ordinary shares and pre-funded warrants at a purchase...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Phase 1 ‘HEAT’ trial of RAD202 for treatment of advanced HER2-positive solid tumors U.S. FDA granted Fast Track Designation for RAD101 to distinguish between recurrent disease and the treatment effect of brain metastases Confirmed guidance of Cash Runway through to mid-2026 SYDNEY, Australia, July 29, 2025 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced financial results for the fiscal year ended June 30, 2025, and provided a...

Vancouver, BC, Canada, July 29, 2025 (GLOBE NEWSWIRE) — WestKam Gold Corp. (TSXV:WKG) (the “Company” or “WestKam”), is providing a bi-weekly default status report in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“). On July 2, 2025 (the “MCTO Announcement”), the Company announced that it had applied to the British Columbia Securities Commission (the “BCSC”) for a management cease trade order (the “MCTO”) in connection with the delay by the Company in filing its interim financial statements, the related management’s discussion and analysis and the related officer certifications for the six month period ended April 30, 2025 (collectively, the “Interim Filings”), before the filing deadline of June 30, 2025 (the “Filing Deadline”) as required under applicable Canadian securities...